Thomas Dorlo

The status of combination therapy for visceral leishmaniasis: an updated review

van Griensven, Johan; Dorlo, Thomas P. C.; Diro, Ermias; Costa, Carlos et al.

Ingår i The Lancet - Infectious diseases, 2024

• DOI för The status of combination therapy for visceral leishmaniasis: an updated review

Pyronaridine: a review of its clinical pharmacology in the treatment of malaria

Chu, Wan-Yu; Dorlo, Thomas P. C.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2406-2418, 2023

• DOI för Pyronaridine: a review of its clinical pharmacology in the treatment of malaria
• Ladda ner fulltext (pdf) av Pyronaridine: a review of its clinical pharmacology in the treatment of malaria

Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk

Damoiseaux, David; Amant, Frédéric; Beijnen, Jos H.; Barnett, Shelby et al.

Ingår i CPT, s. 1931-1944, 2023

• DOI för Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk
• Ladda ner fulltext (pdf) av Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach

Damoiseaux, David; Centanni, Daniel; Beijnen, Jos H.; Amant, Frédéric et al.

Ingår i Clinical Pharmacokinetics, s. 969-980, 2023

• DOI för Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
• Ladda ner fulltext (pdf) av Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.

Musa, Ahmed M; Mbui, Jane; Mohammed, Rezika; Olobo, Joseph et al.

Ingår i Clinical Infectious Diseases, 2022

• DOI för Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.

Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.

Roseboom, Ignace C; Thijssen, Bas; Rosing, Hilde; Alves, Fabiana et al.

Ingår i Journal of chromatography. B, 2022

• DOI för Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.
• Ladda ner fulltext (pdf) av Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

Palić, Semra; Beijnen, Jos H; Dorlo, Thomas P. C.

Ingår i International Journal of Antimicrobial Agents, s. 106459, 2022

• DOI för An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa.

Verrest, Luka; Kip, Anke E; Musa, Ahmed M; Schoone, Gerard J et al.

Ingår i Clinical Infectious Diseases, s. 775-782, 2021

• DOI för Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa.

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.

Verrest, Luka; Wasunna, Monique; Kokwaro, Gilbert; Aman, Rashid et al.

Ingår i Clinical Pharmacokinetics, s. 1463-1473, 2021

• DOI för Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.

Palić, Semra; Kip, Anke E; Beijnen, Jos H; Mbui, Jane et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3260-3268, 2020

• DOI för Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.

Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis

Henninger, Rasmus Hansen; Schouten, Wietse M.; Arana, Byron; Gillon, Jean-Yves et al.

Ingår i Clinical and Translational Science, 2026

• DOI för Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis
• Ladda ner fulltext (pdf) av Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

Chu, Wan-Yu; Singh, Om Prakash; Sundar, Shyam; Mondal, Dinesh et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 437-446, 2026

• DOI för Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing
• Ladda ner fulltext (pdf) av Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Mazariegos Herrera, Andres; Karlsson, Mats O.; Svensson, Elin M.; Dorlo, Thomas P. C.

Ingår i Journal of Antimicrobial Chemotherapy, 2026

• DOI för Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
• Ladda ner fulltext (pdf) av Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis

Chu, Wan-Yu; Singh, Om Prakash; Sundar, Shyam; Pandey, Krishna et al.

Ingår i International Journal of Antimicrobial Agents, 2026

• DOI för Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis
• Ladda ner fulltext (pdf) av Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis

Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study

Chu, Wan-Yu; Schouten, Wietse M.; Mavoko, Hypolite Muhindo; Tshiongo, Japhet Kabalu et al.

Ingår i Clinical Pharmacokinetics, s. 1855-1867, 2025

• DOI för Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study
• Ladda ner fulltext (pdf) av Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study

Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis

Henninger, Rasmus Hansen; Schouten, Wietse M.; Arana, Byron; Gillon, Jean-Yves et al.

Ingår i Clinical and Translational Science, 2026

• DOI för Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis
• Ladda ner fulltext (pdf) av Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

Chu, Wan-Yu; Singh, Om Prakash; Sundar, Shyam; Mondal, Dinesh et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 437-446, 2026

• DOI för Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing
• Ladda ner fulltext (pdf) av Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Mazariegos Herrera, Andres; Karlsson, Mats O.; Svensson, Elin M.; Dorlo, Thomas P. C.

Ingår i Journal of Antimicrobial Chemotherapy, 2026

• DOI för Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
• Ladda ner fulltext (pdf) av Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis

Chu, Wan-Yu; Singh, Om Prakash; Sundar, Shyam; Pandey, Krishna et al.

Ingår i International Journal of Antimicrobial Agents, 2026

• DOI för Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis
• Ladda ner fulltext (pdf) av Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis

Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study

Chu, Wan-Yu; Schouten, Wietse M.; Mavoko, Hypolite Muhindo; Tshiongo, Japhet Kabalu et al.

Ingår i Clinical Pharmacokinetics, s. 1855-1867, 2025

• DOI för Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study
• Ladda ner fulltext (pdf) av Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study

Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole and Hydroxyitraconazole in Sudanese Patients With Eumycetoma.

Chu, Wan-Yu; Fahal, Ahmed H; Ahmed, Eiman Siddig; Bakhiet, Sahar Mubarak et al.

Ingår i Journal of Infectious Diseases, 2025

• DOI för Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole and Hydroxyitraconazole in Sudanese Patients With Eumycetoma.

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies

Schouten, Wietse M.; van Bocxlaer, Katrien; Rosing, Hilde; Huitema, Alwin D. R. et al.

Ingår i Biomedical Chromatography, 2025

• DOI för Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies
• Ladda ner fulltext (pdf) av Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies

Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis

van den Berg, Stefan P. H.; Toorop, Alyssa A.; Hooijberg, Femke; Wolbink, Gertjan et al.

Ingår i CPT, s. 1032-1041, 2025

• DOI för Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis
• Ladda ner fulltext (pdf) av Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study

Schouten, Wietse M.; Van Bocxlaer, Katrien; Rosing, Hilde; Huitema, Alwin D. R. et al.

Ingår i Journal of chromatography. B, 2025

• DOI för Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study
• Ladda ner fulltext (pdf) av Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study

Does one model fit all mAbs?: An evaluation of population pharmacokinetic models

van den Berg, Stefan P. H.; Adolfsen, Philine E. A.; Dorlo, Thomas P. C.; Rispens, Theo

Ingår i mAbs, 2025

• DOI för Does one model fit all mAbs?: An evaluation of population pharmacokinetic models
• Ladda ner fulltext (pdf) av Does one model fit all mAbs?: An evaluation of population pharmacokinetic models

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia: authors' response

Dorlo, Thomas P. C.; Chu, Wan-Yu

Ingår i Journal of Antimicrobial Chemotherapy, s. 1162-1164, 2025

• DOI för Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia: authors' response

Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model–Derived Tapering Strategies for Patients With Rheumatoid Arthritis

Hooijberg, Femke; van den Berg, Stefan P. H.; Layegh, Zohra; Leeuw, Maureen et al.

Ingår i Therapeutic Drug Monitoring, s. 337-345, 2025

• DOI för Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model–Derived Tapering Strategies for Patients With Rheumatoid Arthritis

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices

Schouten, Wietse M; Van Bocxlaer, Katrien; Rosing, Hilde; Huitema, Alwin D R et al.

Ingår i Journal of chromatography. B, 2025

• DOI för Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices
• Ladda ner fulltext (pdf) av Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models

Damoiseaux, David; Beijnen, Jos H.; Huitema, Alwin D. R.; Dorlo, Thomas P. C.

Ingår i Drug Metabolism And Disposition, s. 1217-1223, 2024

• DOI för Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models
• Ladda ner fulltext (pdf) av Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia

Palic, Semra; Chu, Wan-Yu; Sundar, Shyam; Mondal, Dinesh et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1547-1554, 2024

• DOI för Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia
• Ladda ner fulltext (pdf) av Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia

Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication

Hooijberg, Femke; Layegh, Zohra; Leeuw, Maureen; Boekel, Laura et al.

Ingår i Therapeutic Drug Monitoring, s. 410-414, 2024

• DOI för Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication

Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa

Chu, Wan-Yu; Verrest, Luka; Younis, Brima M; Musa, Ahmed M et al.

Ingår i Journal of Infectious Diseases, 2024

• DOI för Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa
• Ladda ner fulltext (pdf) av Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa

Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal, Ahmed H.; Ahmed, Eiman Siddig; Bakhiet, Sahar Mubarak; Bakhiet, Osama Elhadi et al.

Ingår i The Lancet - Infectious diseases, s. 1254-1265, 2024

• DOI för Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach

Ramisetty, Bhargavi Srija; Yang, Sihyung; Dorlo, Thomas P.C.; Wang, Michael Zhuo

Ingår i Antimicrobial Agents and Chemotherapy, 2024

• DOI för Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach

Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease

Chu, Wan-Yu; Nijman, Maaike; Stegeman, Raymond; Breur, Johannes M. P. J. et al.

Ingår i Clinical Pharmacokinetics, s. 1205-1220, 2024

• DOI för Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease
• Ladda ner fulltext (pdf) av Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease

Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling

Koele, Simon E; Dorlo, Thomas P. C.; Upton, Caryn M; Aarnoutse, Rob E et al.

Ingår i CPT, s. 374-385, 2024

• DOI för Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling
• Ladda ner fulltext (pdf) av Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood

Schouten, Wietse M.; Roseboom, Ignace C.; Lucas, Luc; Tshiongo, Japhet Kabalu et al.

Ingår i Journal of Pharmaceutical and Biomedical Analysis, 2024

• DOI för Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood
• Ladda ner fulltext (pdf) av Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood

Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model

Verrest, Luka; Monnerat, Severine; Musa, Ahmed M.; Mbui, Jane et al.

Ingår i PLoS Neglected Tropical Diseases, 2024

• DOI för Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model
• Ladda ner fulltext (pdf) av Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model

Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs

Roseboom, Ignace C; Rosing, Hilde; Beijnen, Jos H; Dorlo, Thomas P. C.

Ingår i Biomedical Chromatography, 2023

• DOI för Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs
• Ladda ner fulltext (pdf) av Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs

A physiologically based pharmacokinetic model for [Ga-68]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Siebinga, Hinke; de Wit-van der Veen, Berlinda J. J.; Beijnen, Jos H.; Dorlo, Thomas P. C. et al.

Ingår i EJNMMI Research, 2023

• DOI för A physiologically based pharmacokinetic model for [Ga-68]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
• Ladda ner fulltext (pdf) av A physiologically based pharmacokinetic model for [Ga-68]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial

Djimde, Moussa; Tshiongo, Japhet Kabalu; Muhindo, Hypolite Mavoko; Tinto, Halidou et al.

Ingår i BMJ Open, 2023

• DOI för Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial
• Ladda ner fulltext (pdf) av Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

Janssen, J. M.; Damoiseaux, D.; van Hasselt, J. G. C.; Amant, F. C. H. et al.

Ingår i Clinical Pharmacokinetics, s. 1157-1167, 2023

• DOI för Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
• Ladda ner fulltext (pdf) av Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function

Molenaar‐Kuijsten, Laura; Pieters, Tobias T.; Veldhuis, Wouter B.; Moeskops, Pim et al.

Ingår i British Journal of Clinical Pharmacology, s. 3016-3025, 2023

• DOI för Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function

High accumulation of nivolumab in human breast milk: A case report

de Jong, Karen; Damoiseaux, David; Pluim, Dick; Rosing, Hilde et al.

Ingår i Biomedicine and Pharmacotherapy, 2023

• DOI för High accumulation of nivolumab in human breast milk: A case report
• Ladda ner fulltext (pdf) av High accumulation of nivolumab in human breast milk: A case report

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

Van der Heijden, Lisa T.; Nijstad, A. Laura; Uittenboogaard, Aniek; Beijnen, Jos H. et al.

Ingår i Therapeutic Drug Monitoring, s. 354-363, 2023

• DOI för Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens

van der Heijden, Lisa; van Nuland, Merel; Beijnen, Jos; Huitema, Alwin et al.

Ingår i Clinical and Translational Science, s. 258-268, 2023

• DOI för A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens

Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk

Damoiseaux, David; Amant, Frédéric; Beijnen, Jos H.; Barnett, Shelby et al.

Ingår i CPT, s. 1931-1944, 2023

• DOI för Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk
• Ladda ner fulltext (pdf) av Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk

The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

van Der Heijden, L. T.; Steeghs, N.; Beijnen, J. H.; Huitema, A. D. R. et al.

Ingår i Clinical and Translational Science, s. 2557-2564, 2023

• DOI för The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib
• Ladda ner fulltext (pdf) av The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study

Younis, Brima Musa; Mudawi Musa, Ahmed; Monnerat, Severine; Saeed, Mohammed Abdelrahim et al.

Ingår i PLoS Neglected Tropical Diseases, 2023

• DOI för Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study
• Ladda ner fulltext (pdf) av Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest, Luka; Roseboom, Ignace C.; Wasunna, Monique; Mbui, Jane et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2702-2714, 2023

• DOI för Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
• Ladda ner fulltext (pdf) av Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of ¹⁷⁷Lu-PSMA-617 in prostate cancer patients

Siebinga, Hinke; Privé, Bastiaan M.; Peters, Steffie M. B.; Nagarajah, James et al.

Ingår i CPT, s. 1060-1071, 2023

• DOI för Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of ¹⁷⁷Lu-PSMA-617 in prostate cancer patients
• Ladda ner fulltext (pdf) av Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of ¹⁷⁷Lu-PSMA-617 in prostate cancer patients

Predicting [¹⁷⁷Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [⁶⁸Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling

Siebinga, Hinke; de van der Veen, Berlinda J.; Beijnen, Jos H.; Stokkel, Marcel P. M. et al.

Ingår i EJNMMI Physics, 2023

• DOI för Predicting [¹⁷⁷Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [⁶⁸Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
• Ladda ner fulltext (pdf) av Predicting [¹⁷⁷Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [⁶⁸Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling

Comment on "Dosing implications for liposomal amphotericin B in pregnancy"

Chu, Wan-Yu; Dorlo, Thomas P. C.

Ingår i Pharmacotherapy, s. 991-991, 2023

• DOI för Comment on "Dosing implications for liposomal amphotericin B in pregnancy"

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach

Damoiseaux, David; Centanni, Daniel; Beijnen, Jos H.; Amant, Frédéric et al.

Ingår i Clinical Pharmacokinetics, s. 969-980, 2023

• DOI för Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
• Ladda ner fulltext (pdf) av Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach

Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series.

Damoiseaux, David; Calpe, Silvia; Rosing, Hilde; Beijnen, Jos H et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 404-410, 2022

• DOI för Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series.

Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer.

Molenaar-Kuijsten, Laura; Verheijen, Remy B; Jacobs, Bart A W; Thijssen, Bas et al.

Ingår i Therapeutic Drug Monitoring, s. 520-526, 2022

• DOI för Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer.

Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates

Chu, Wan-Yu; Allegaert, Karel; Dorlo, Thomas P. C.; Huitema, Alwin D R

Ingår i Clinical Pharmacokinetics, s. 1545-1558, 2022

• DOI för Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates
• Ladda ner fulltext (pdf) av Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.

Musa, Ahmed M; Mbui, Jane; Mohammed, Rezika; Olobo, Joseph et al.

Ingår i Clinical Infectious Diseases, 2022

• DOI för Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.

Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022

Hinds, Terry D.; Valoti, Massimo; Lai, Yurong; Dorlo, Thomas P. C. et al.

Ingår i Frontiers in Pharmacology, 2022

• DOI för Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022
• Ladda ner fulltext (pdf) av Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022

Editorial: Therapeutic Drug Monitoring (TDM)

Simeoli, Raffaele; Dorlo, Thomas P. C.; Hanff, Lidwien M; Huitema, Alwin D R et al.

Ingår i Frontiers in Pharmacology, s. 931843, 2022

• DOI för Editorial: Therapeutic Drug Monitoring (TDM)
• Ladda ner fulltext (pdf) av Editorial: Therapeutic Drug Monitoring (TDM)

Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib

Damoiseaux, David; Li, Wenlong; Beijnen, Jos H; Schinkel, Alfred H et al.

Ingår i Journal of Pharmaceutical Sciences, s. 495-504, 2022

• DOI för Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.

Janssen, Julie M; Verheijen, Remy B; van Duijl, Tirsa T; Lin, Lishi et al.

Ingår i Clinical and Translational Science, s. 1916-1925, 2022

• DOI för Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.
• Ladda ner fulltext (pdf) av Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.

Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates

Chu, Wan-Yu; Annink, Kim V; Nijstad, A Laura; Maiwald, Christian A et al.

Ingår i Clinical Pharmacokinetics, s. 321-333, 2022

• DOI för Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates

Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.

Roseboom, Ignace C; Thijssen, Bas; Rosing, Hilde; Alves, Fabiana et al.

Ingår i Journal of Pharmaceutical and Biomedical Analysis, s. 114402, 2022

• DOI för Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.
• Ladda ner fulltext (pdf) av Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.

van Eijk, Maarten; Yu, Huixin; Sawicki, Emilia; de Weger, Vincent A et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 71-82, 2022

• DOI för Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.
• Ladda ner fulltext (pdf) av Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.

Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.

Roseboom, Ignace C; Thijssen, Bas; Rosing, Hilde; Alves, Fabiana et al.

Ingår i Journal of chromatography. B, 2022

• DOI för Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.
• Ladda ner fulltext (pdf) av Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.

Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.

Roseboom, Ignace C; Thijssen, Bas; Rosing, Hilde; Alves, Fabiana et al.

Ingår i Journal of chromatography. B, 2022

• DOI för Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.
• Ladda ner fulltext (pdf) av Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

Palić, Semra; Beijnen, Jos H; Dorlo, Thomas P. C.

Ingår i International Journal of Antimicrobial Agents, s. 106459, 2022

• DOI för An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

No evidence for cardiotoxicity of miltefosine

Dorlo, Thomas P. C.

Ingår i Anais Brasileiros de Dermatologia, s. 548-549, 2022

• DOI för No evidence for cardiotoxicity of miltefosine
• Ladda ner fulltext (pdf) av No evidence for cardiotoxicity of miltefosine

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs.

Damoiseaux, David; Li, Wenlong; Martínez-Chávez, Alejandra; Beijnen, Jos H et al.

Ingår i Pharmaceuticals (Basel, Switzerland), 2022

• DOI för Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs.

Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).

Janssen, Julie M; Van Calsteren, Kristel; Dorlo, Thomas P C; Halaska, Michael J et al.

Ingår i Clinical Pharmacokinetics, s. 775-784, 2021

• DOI för Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).

Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.

Molenaar-Kuijsten, Laura; Jacobs, Bart Albertus Wilhelmus; Kurk, Sophie Alberdine; May, Anne Maria et al.

Ingår i Cancer Medicine, s. 4781-4789, 2021

• DOI för Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.

Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.

Janssen, Julie M; Jacobs, Bart A W; Roosendaal, Jeroen; Derissen, Ellen J B et al.

Ingår i AAPS Journal, s. 23, 2021

• DOI för Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.

Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment

Boosman, René J; Dorlo, Thomas P. C.; de Rouw, Nikki; Burgers, Jacobus A et al.

Ingår i International Journal of Cancer, s. 1576-1584, 2021

• DOI för Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment

Relapsing leishmanial arthritis: report of a tricky localization and evidence of miltefosine diffusion in synovial fluid.

Contejean, Adrien; Ayral, Xavier; Dorlo, Thomas P. C.; Roseboom, Ignace C et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2740-2741, 2021

• DOI för Relapsing leishmanial arthritis: report of a tricky localization and evidence of miltefosine diffusion in synovial fluid.

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of ⁶⁸Ga-DOTATATE in patients without neuroendocrine tumors

Siebinga, H; de Wit-van der Veen, B J; Beijnen, J H; Stokkel, M P M et al.

Ingår i EJNMMI Research, 2021

• DOI för A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of ⁶⁸Ga-DOTATATE in patients without neuroendocrine tumors
• Ladda ner fulltext (pdf) av A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of ⁶⁸Ga-DOTATATE in patients without neuroendocrine tumors

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa.

Verrest, Luka; Kip, Anke E; Musa, Ahmed M; Schoone, Gerard J et al.

Ingår i Clinical Infectious Diseases, s. 775-782, 2021

• DOI för Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa.

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.

van Eijk, Maarten; Pluim, Dick; Dorlo, Thomas P C; Marchetti, Serena et al.

Ingår i The Pharmacogenomics Journal, s. 336-345, 2021

• DOI för Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.

Kip, Anke E; Blesson, Séverine; Alves, Fabiana; Wasunna, Monique et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1258-1268, 2021

• DOI för Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.

Verrest, Luka; Wilthagen, Erica A; Beijnen, Jos H; Huitema, Alwin D R et al.

Ingår i Clinical Pharmacokinetics, s. 1149-1169, 2021

• DOI för Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.

Verrest, Luka; Wasunna, Monique; Kokwaro, Gilbert; Aman, Rashid et al.

Ingår i Clinical Pharmacokinetics, s. 1463-1473, 2021

• DOI för Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.

Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.

Yu, Huixin; Janssen, Julie M; de Weger, Vincent A; Nuijen, Bastiaan et al.

Ingår i Investigational new drugs, s. 1526-1532, 2020

• DOI för Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.

Langenhorst, Jurgen B; Dorlo, Thomas P C; van Kesteren, Charlotte; van Maarseveen, Erik M et al.

Ingår i CPT, s. 272-281, 2020

• DOI för Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors.

de Vries Schultink, Aurelia H M; Bol, Kees; Doornbos, Robert P; Murat, Anastasia et al.

Ingår i Clinical Pharmacokinetics, s. 875-884, 2020

• DOI för Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors.

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

Janssen, Julie M; Dorlo, Thomas P C; Steeghs, Neeltje; Beijnen, Jos H et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 494-505, 2020

• DOI för Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma.

Roseboom, Ignace C; Thijssen, Bas; Rosing, Hilde; Mbui, Jane et al.

Ingår i Journal of Pharmaceutical and Biomedical Analysis, s. 113245, 2020

• DOI för Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma.

Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs.

Janssen, Julie M; Dorlo, Thomas P C; Beijnen, Jos H; Huitema, Alwin D R

Ingår i Therapeutic Drug Monitoring, s. 532-539, 2020

• DOI för Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs.

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.

Palić, Semra; Kip, Anke E; Beijnen, Jos H; Mbui, Jane et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3260-3268, 2020

• DOI för Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.

Schmidt, Keith T; Huitema, Alwin D R; Dorlo, Thomas P C; Peer, Cody J et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 475-486, 2020

• DOI för Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.

Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds.

Roseboom, Ignace C; Rosing, Hilde; Beijnen, Jos H; Dorlo, Thomas P C

Ingår i Journal of Pharmaceutical and Biomedical Analysis, s. 113590, 2020

• DOI för Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds.

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Janssen, Julie M; Dorlo, T P C; Niewerth, D; Wilhelm, A J et al.

Ingår i Clinical Pharmacokinetics, s. 207-216, 2020

• DOI för A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Palić, Semra; Bhairosing, Patrick; Beijnen, Jos H; Dorlo, Thomas P C

Ingår i Antimicrobial Agents and Chemotherapy, 2019

• DOI för Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag, Marie-Rose B S; de Vries Schultink, Aurelia H M; Koolen, Stijn L W; Wijngaard, Sophie et al.

Ingår i Pharmaceutical research, s. 33, 2019

• DOI för Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Langenhorst, Jurgen B; Dorlo, Thomas P C; van Maarseveen, Erik M; Nierkens, Stefan et al.

Ingår i Clinical Pharmacokinetics, s. 627-637, 2019

• DOI för Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Crombag, Marie-Rose B S; Koolen, Stijn L W; Wijngaard, Sophie; Joerger, Markus et al.

Ingår i Pharmaceutical research, s. 163, 2019

• DOI för Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Langenhorst, J B; van Kesteren, C; van Maarseveen, E M; Dorlo, T P C et al.

Ingår i Blood Advances, s. 2179-2187, 2019

• DOI för Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

Crombag, Marie-Rose B S; Dorlo, Thomas P C; van der Pan, Ellen; van Straten, Anoek et al.

Ingår i Pharmaceutical research, s. 181, 2019

• DOI för Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.

Mbui, Jane; Olobo, Joseph; Omollo, Raymond; Solomos, Alexandra et al.

Ingår i Clinical Infectious Diseases, s. 1530-1538, 2019

• DOI för Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.

Safe mass drug administration for neglected tropical diseases.

de Souza, Dziedzom K; Dorlo, Thomas P C

Ingår i The Lancet Global Health, 2018

• DOI för Safe mass drug administration for neglected tropical diseases.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Kip, Anke E; Wasunna, Monique; Alves, Fabiana; Schellens, Jan H M et al.

Ingår i Frontiers in Cellular and Infection Microbiology, s. 181, 2018

• DOI för Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

de Vries Schultink, Aurelia H M; Boekhout, Annelies H; Gietema, Jourik A; Burylo, Artur M et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 431-442, 2018

• DOI för Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip, Anke E; Castro, María Del Mar; Gomez, Maria Adelaida; Cossio, Alexandra et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2104-2111, 2018

• DOI för Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria

Lohy Das, Jesmin; Rulisa, Stephen; de Vries, Peter J.; Mens, Petra F. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2018

• DOI för Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Adriaensen, Wim; Dorlo, Thomas P C; Vanham, Guido; Kestens, Luc et al.

Ingår i Frontiers in Immunology, s. 1943, 2017

• DOI för Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Letter by Dorlo Regarding Article, "Acupuncture Therapy and Incidence of Depression After Stroke".

Dorlo, Thomas P C

Ingår i Stroke, 2017

• DOI för Letter by Dorlo Regarding Article, "Acupuncture Therapy and Incidence of Depression After Stroke".

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis

Castro, María Del Mar; Gomez, Maria Adelaida; Kip, Anke E.; Cossio, Alexandra et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2017

• DOI för Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Kip, A E; Kiers, K C; Rosing, H; Schellens, J H M et al.

Ingår i Journal of Pharmaceutical and Biomedical Analysis, s. 160-166, 2017

• DOI för Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Evaluation Of Macrophage Activation Marker Neopterin As A Pharmacodynamic Biomarker In Visceral Leishmaniasis

Kip, Antonia E.; Musa, Ahmed; Khalil, Eltahiri A.; Wassuna, Monique et al.

Ingår i American Journal of Tropical Medicine and Hygiene, s. 162-163, 2017

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

Dorlo, Thomas P. C.; Kip, Anke E.; Younis, Brima M.; Ellis, Sally J. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3131-3140, 2017

• DOI för Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
• Ladda ner fulltext (pdf) av Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

Treatment of visceral leishmaniasis: pitfalls and stewardship

Dorlo, Thomas P. C.; Ostyn, Bart A.; Uranw, Surendra; Dujardin, Jean-Claude et al.

Ingår i The Lancet - Infectious diseases, s. 777-778, 2016

Poverty-Related Diseases College: a virtual African-European network to build research capacity

Dorlo, Thomas P. C.; Fernndez, Carmen; Troye-Blomberg, Marita; De Vries, Peter J. et al.

Ingår i BMJ Global Health, 2016

• DOI för Poverty-Related Diseases College: a virtual African-European network to build research capacity
• Ladda ner fulltext (pdf) av Poverty-Related Diseases College: a virtual African-European network to build research capacity

Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis

Fortin, Anny; Dorlo, Thomas P. C.; Hendrickx, Sarah; Maes, Louis

Ingår i Journal of Antimicrobial Chemotherapy, s. 1892-1898, 2016

• DOI för Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis

Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection

Kip, A E; Rosing, H; Hillebrand, M J X; Blesson, S et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 2081-2089, 2016

• DOI för Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection
• Ladda ner fulltext (pdf) av Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

Martial, Lisa C; Brüggemann, Roger J M; Schouten, Jeroen A; van Leeuwen, Henk J et al.

Ingår i Clinical Pharmacokinetics, s. 723-733, 2016

• DOI för Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
• Ladda ner fulltext (pdf) av Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: Impact on Intracellular Survival of Leishmania (Viannia) panamensis

Dohmen, Luuk C T; Navas, Adriana; Vargas, Deninson Alejandro; Gregory, David J et al.

Ingår i Journal of Biological Chemistry, s. 9638-9647, 2016

• DOI för Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: Impact on Intracellular Survival of Leishmania (Viannia) panamensis

Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint

Ravinetto, Raffaella; De Weggheleire, Anja; Dorlo, Thomas P. C.; Francque, Sven et al.

Ingår i Tropical medicine & international health, s. 1490-1495, 2016

• DOI för Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint
• Ladda ner fulltext (pdf) av Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint

Pharmacokinetics and pharmacodynamics of oral oleylphosphocholine in a hamster model of visceral leishmaniasis

Fortin, A.; Dorlo, Thomas P. C.; Matheeussen, A.; Hendrickx, S. et al.

Ingår i Tropical medicine & international health, s. 222-222, 2015

• DOI för Pharmacokinetics and pharmacodynamics of oral oleylphosphocholine in a hamster model of visceral leishmaniasis

Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Roy, Sharon L; Atkins, Jane T; Gennuso, Rosemaria; Kofos, Danny et al.

Ingår i Parasitology Research, s. 4431-9, 2015

• DOI för Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Kip, Anke E; Balasegaram, Manica; Beijnen, Jos H; Schellens, Jan H M et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 1-14, 2015

• DOI för Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Kip, A E; Rosing, H; Hillebrand, M J X; Castro, M M et al.

Ingår i Journal of chromatography. B, s. 57-62, 2015

• DOI för Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome

Kreeftmeijer-Vegter, A. R.; Dorlo, Thomas P. C.; Gruppen, M. P.; de Boer, A. et al.

Ingår i British Journal of Clinical Pharmacology, s. 242-252, 2015

• DOI för Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome

LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.

Blum, Johannes; Buffet, Pierre; Visser, Leo; Harms, Gundel et al.

Ingår i Journal of Travel Medicine, s. 116-29, 2014

• DOI för LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.

Dorlo, Thomas P C; Rijal, Suman; Ostyn, Bart; de Vries, Peter J et al.

Ingår i Journal of Infectious Diseases, s. 146-53, 2014

• DOI för Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.

Khalil, Eltahir A G; Weldegebreal, Teklu; Younis, Brima M; Omollo, Raymond et al.

Ingår i PLoS Neglected Tropical Diseases, 2014

• DOI för Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.

Different liposomal amphotericin B formulations for visceral leishmaniasis.

Dorlo, Thomas P C; Balasegaram, Manica

Ingår i The Lancet Global Health, 2014

• DOI för Different liposomal amphotericin B formulations for visceral leishmaniasis.

Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.

Ostyn, Bart; Hasker, Epco; Dorlo, Thomas P C; Rijal, Suman et al.

Ingår i PLOS ONE, 2014

• DOI för Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.

The global impact of Indian generics on access to health.

Ravinetto, Raffaella M; Dorlo, Thomas P C; Caudron, Jean-Michel; Prashanth, N S

Ingår i Indian journal of medical ethics, s. 118-20, 2013

• DOI för The global impact of Indian generics on access to health.

Please, let not Western quackery replace traditional medicine in Africa.

Renckens, Cees N M; Dorlo, Thomas P C

Ingår i Tropical medicine & international health, s. 242-4, 2013

• DOI för Please, let not Western quackery replace traditional medicine in Africa.

[Concomitant use of proton pump inhibitors and systemic corticosteroids].

Dorlo, Thomas P C; Jager, Nynke G L; Beijnen, Jos H; Schellens, Jan H M

Ingår i Nederlandsch tijdschrift voor geneeskunde, 2013

Reply to Arya and Agarwal.

Dorlo, Thomas P C; Ostyn, Bart A; Beijnen, Jos H; Boelaert, Marleen et al.

Ingår i Clinical Infectious Diseases, s. 917-8, 2013

• DOI för Reply to Arya and Agarwal.

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Rijal, Suman; Ostyn, Bart; Uranw, Surendra; Rai, Keshav et al.

Ingår i Clinical Infectious Diseases, s. 1530-8, 2013

• DOI för Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.

Uranw, Surendra; Ostyn, Bart; Dorlo, Thomas P C; Hasker, Epco et al.

Ingår i Tropical medicine & international health, s. 179-87, 2013

• DOI för Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.

Universal access to quality medicines: prioritisation of a-priori solutions.

Dorlo, Thomas P C; Boelaert, Marleen; Beijnen, Jos H; Ravinetto, Raffaella

Ingår i The Lancet - Infectious diseases, s. 829-30, 2012

• DOI för Universal access to quality medicines: prioritisation of a-priori solutions.

Commentary: Substandard medicines are the priority for neglected tropical diseases.

Dorlo, Thomas P C; Ravinetto, Raffaella M; Beijnen, Jos H; Boelaert, Marleen

Ingår i The BMJ, 2012

• DOI för Commentary: Substandard medicines are the priority for neglected tropical diseases.

Characterization and identification of suspected counterfeit miltefosine capsules.

Dorlo, Thomas P C; Eggelte, Teunis A; de Vries, Peter J; Beijnen, Jos H

Ingår i The Analyst, s. 1265-74, 2012

• DOI för Characterization and identification of suspected counterfeit miltefosine capsules.

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.

Byakika-Kibwika, Pauline; Lamorde, Mohammed; Okaba-Kayom, Violet; Mayanja-Kizza, Harriet et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1217-23, 2012

• DOI för Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.

Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.

Dorlo, Thomas P C; Balasegaram, Manica; Lima, María Angeles; de Vries, Peter J et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1996-2004, 2012

• DOI för Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

Dorlo, Thomas P C; Huitema, Alwin D R; Beijnen, Jos H; de Vries, Peter J

Ingår i Antimicrobial Agents and Chemotherapy, s. 3864-72, 2012

• DOI för Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.

Dorlo, Thomas P C; Eggelte, Teunis A; Schoone, Gerard J; de Vries, Peter J et al.

Ingår i PLoS Neglected Tropical Diseases, 2012

• DOI för A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Dorlo, Thomas P C; Balasegaram, Manica; Beijnen, Jos H; de Vries, Peter J

Ingår i Journal of Antimicrobial Chemotherapy, s. 2576-97, 2012

• DOI för Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

Omollo, Raymond; Alexander, Neal; Edwards, Tansy; Khalil, Eltahir A G et al.

Ingår i Trials, s. 166, 2011

• DOI för Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.

Dorlo, Thomas P C; van Thiel, Pieter P A M; Schoone, Gerard J; Stienstra, Ymkje et al.

Ingår i PLoS Neglected Tropical Diseases, 2011

• DOI för Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.

Severe encephalopathy and polyneuropathy induced by dichloroacetate.

Brandsma, Dieta; Dorlo, Thomas P C; Haanen, John H; Beijnen, Jos H et al.

Ingår i Journal of Neurology, s. 2099-100, 2010

• DOI för Severe encephalopathy and polyneuropathy induced by dichloroacetate.

Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia

Dorlo, Thomas P C; Kager, Piet A

Ingår i Transactions of the Royal Society of Tropical Medicine and Hygiene, s. 84-5; author reply 85, 2010

• DOI för Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Dorlo, Thomas P C; van Thiel, Pieter P A M; Huitema, Alwin D R; Keizer, Ron J et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 2855-60, 2008

• DOI för Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Pentamidine dosage: a base/salt confusion.

Dorlo, Thomas P C; Kager, Piet A

Ingår i PLoS Neglected Tropical Diseases, 2008

• DOI för Pentamidine dosage: a base/salt confusion.

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

Dorlo, Thomas P C; Hillebrand, Michel J X; Rosing, Hilde; Eggelte, Teunis A et al.

Ingår i Journal of chromatography. B, s. 55-62, 2008

• DOI för Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

[Miltefosine: a new remedy for leishmaniasis].

Dorlo, T P C; Eggelte, T A; Beijnen, J H; de Vries, P J

Ingår i Nederlandsch tijdschrift voor geneeskunde, s. 2697-701, 2006

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis

Damoiseaux, David; Schinkel, Alfred H.; Beijnen, Jos H.; Huitema, Alwin D. R. et al.

Ingår i Clinical and Translational Science, 2024

• DOI för Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis

The status of combination therapy for visceral leishmaniasis: an updated review

van Griensven, Johan; Dorlo, Thomas P. C.; Diro, Ermias; Costa, Carlos et al.

Ingår i The Lancet - Infectious diseases, 2024

• DOI för The status of combination therapy for visceral leishmaniasis: an updated review

Pyronaridine: a review of its clinical pharmacology in the treatment of malaria

Chu, Wan-Yu; Dorlo, Thomas P. C.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2406-2418, 2023

• DOI för Pyronaridine: a review of its clinical pharmacology in the treatment of malaria
• Ladda ner fulltext (pdf) av Pyronaridine: a review of its clinical pharmacology in the treatment of malaria

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

Kip, Anke E.; Schellens, Jan H. M.; Beijnen, Jos H.; Dorlo, Thomas P. C.

Ingår i Clinical Pharmacokinetics, s. 151-176, 2018

• DOI för Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
• Ladda ner fulltext (pdf) av Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Verrest, Luka; Dorlo, Thomas P. C.

Ingår i Clinical Pharmacokinetics, s. 583-606, 2017

• DOI för Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.